Cargando…

Decentral gene expression analysis for ER+/Her2− breast cancer: results of a proficiency testing program for the EndoPredict assay

Gene expression profiles provide important information about the biology of breast tumors and can be used to develop prognostic tests. However, the implementation of quantitative RNA-based testing in routine molecular pathology has not been accomplished, so far. The EndoPredict assay has recently be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Denkert, Carsten, Kronenwett, Ralf, Schlake, Werner, Bohmann, Kerstin, Penzel, Roland, Weber, Karsten E., Höfler, Heinz, Lehmann, Ulrich, Schirmacher, Peter, Specht, Katja, Rudas, Margaretha, Kreipe, Hans-Heinrich, Schraml, Peter, Schlake, Gudrun, Bago-Horvath, Zsuzsanna, Tiecke, Frank, Varga, Zsuzsanna, Moch, Holger, Schmidt, Marcus, Prinzler, Judith, Kerjaschki, Dontscho, Sinn, Bruno Valentin, Müller, Berit Maria, Filipits, Martin, Petry, Christoph, Dietel, Manfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3306560/ https://www.ncbi.nlm.nih.gov/pubmed/22371223 http://dx.doi.org/10.1007/s00428-012-1204-4

Ejemplares similares

Decentral gene expression analysis: analytical validation of the Endopredict genomic multianalyte breast cancer prognosis test
por: Kronenwett, Ralf, et al.
Publicado: (2012)

Comparison of the RNA-based EndoPredict multigene test between core biopsies and corresponding surgical breast cancer sections
por: Müller, Berit Maria, et al.
Publicado: (2012)

Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

Correction: Comparison of EndoPredict and Oncotype DX Test Results in Hormone Receptor Positive Invasive Breast Cancer
por: Varga, Zsuzsanna, et al.
Publicado: (2013)

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions
por: Müller, Berit Maria, et al.
Publicado: (2013)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients
por: Dubsky, P, et al.
Publicado: (2013)

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer
por: Dubsky, P., et al.
Publicado: (2013)

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial
por: Fitzal, F, et al.
Publicado: (2015)

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
por: Rüschoff, Josef, et al.
Publicado: (2010)

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone
por: Sestak, Ivana, et al.
Publicado: (2019)

Putting the brakes on mammary tumorigenesis: Loss of STAT1 predisposes to intraepithelial neoplasias
por: Schneckenleithner, Christine, et al.
Publicado: (2011)

Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict)
por: Jank, Paul, et al.
Publicado: (2021)

Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index: A TransATAC Study
por: Buus, Richard, et al.
Publicado: (2021)

EndoPredict(®) in early hormone receptor-positive, HER2-negative breast cancer
por: Almstedt, K., et al.
Publicado: (2020)

Decision impact and feasibility of different ASCO-recommended biomarkers in early breast cancer: Prospective comparison of molecular marker EndoPredict and protein marker uPA/PAI-1
por: Ettl, Johannes, et al.
Publicado: (2017)

mRNA as novel technology for passive immunotherapy
por: Schlake, Thomas, et al.
Publicado: (2018)

Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients
por: Wimmer, Kerstin, et al.
Publicado: (2023)

Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2− breast cancer patients: results from the GEICAM 9906 trial
por: Martin, Miguel, et al.
Publicado: (2014)

From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis
por: Brase, Jan C., et al.
Publicado: (2013)

Subjective Cognitive Fatigue and Autonomic Abnormalities in Multiple Sclerosis Patients
por: Sander, Carina, et al.
Publicado: (2017)

Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer
por: Constantinidou, Anastasia, et al.
Publicado: (2022)

Predicting Expected Absolute Chemotherapy Treatment Benefit in Women With Early-Stage Breast Cancer Using EndoPredict, an Integrated 12-Gene Clinicomolecular Assay
por: Soliman, Hatem, et al.
Publicado: (2019)

Preanalytical variables and performance of diagnostic RNA-based gene expression analysis in breast cancer
por: Poremba, Christopher, et al.
Publicado: (2014)

SABCS 2017 pathology: from bench to bedside
por: Bago-Horvath, Zsuzsanna
Publicado: (2018)

Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells
por: Hantusch, Brigitte, et al.
Publicado: (2007)

Microdissection and Molecular Analysis of Single Cells or Small Cell Clusters in Pathology and Diagnosis – Significance and Challenges
por: Heinmöller, E., et al.
Publicado: (2002)

Cost-Effectiveness Analysis of Prognostic Gene Expression Signature-Based Stratification of Early Breast Cancer Patients
por: Blank, Patricia R., et al.
Publicado: (2014)

Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
por: Martin, Miguel, et al.
Publicado: (2016)

Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy
por: Varga, Zsuzsanna, et al.
Publicado: (2022)

Multiplex imaging of breast cancer lymph node metastases identifies prognostic single-cell populations independent of clinical classifiers
por: Fischer, Jana Raja, et al.
Publicado: (2023)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

Residual urinary extracellular vesicles in ultracentrifugation supernatants after hydrostatic filtration dialysis enrichment
por: Musante, Luca, et al.
Publicado: (2016)

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression
por: Müller, Berit Maria, et al.
Publicado: (2013)

Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer
por: Bartsch, Rupert, et al.
Publicado: (2009)

Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry
por: Singer, C.F., et al.
Publicado: (2022)

Selection of scFv Antibody Fragments Binding to Human Blood versus Lymphatic Endothelial Surface Antigens by Direct Cell Phage Display
por: Keller, Thomas, et al.
Publicado: (2015)

Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
por: Zhou, Qing, et al.
Publicado: (2022)

Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals
por: Thess, Andreas, et al.
Publicado: (2015)

Salivary IL-1ß as an Objective Measure for Fatigue in Multiple Sclerosis?
por: Hanken, Katrin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tchri64f3btnc1091q25ieel0i